ClinicalTrials.gg

Hemophilia A clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 844 studies for Hemophilia A across more than 10 countries. 136 are recruiting or about to start. 779 of them are mainly about Hemophilia A (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 945 studies for Hemophilia A. How that becomes 843 here

This page counts the studies the registry files under Hemophilia A, and those it files under no condition that list Hemophilia Athemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 945Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −75List Hemophilia A as a condition, but the registry did not file them under itMost often written as “Hemophilia B” (45), “Haemophilia B” (11), and “Acquired Hemophilia A” (10). The registry filed them under other conditions only, most often Hemophilia B (57) and Factor 8 deficiency, acquired (11).
  3. −32Match it another way7 name it in the title, 1 in a keyword, and 24 by a synonym or other text the search reads.
  4. 838Counted here and found by its search49 of them list Hemophilia A in their own words; the registry filed them under no condition.
  5. +5
    Counted here, but its search does not find them
  6. 843The count on this page

Status

Completed
501
Recruiting
88
Status unknown
81
Terminated
60
Active, not recruiting
43
Not yet recruiting
36

Phase

Phase 3
169
Phase 1
102
Phase 2
80
Phase 4
77
Early Phase 1
7

Where

United States
300
Spain
180
France
157
United Kingdom
155
Italy
151
Germany
142

Who develops what

Add Hemophilia A to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 17 programs from 14 companies, 17 with this as their studies’ main aim; 13 with a live phase 3 study; 12 primary completions in the next 12 months. Compare Hoffmann-La Roche, Novo Nordisk and Sanofi here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
F8 protein, humanRecent, limitedPhase 4 trial recorded
Evidence
  • NCT07416526 · Hoffmann-La Roche · Phase 3 · live · comparator · “Human Coagulation Factor VIII” · registered Feb 2026
  • NCT00989196 · Octapharma · Phase 2 · comparator · “Kogenate FS” · registered Sep 2009
  • NCT00666406 · Takeda · Phase 4 · comparator · “Recombinant Factor VIII (rAHF)” · registered Apr 2008
Bayer53% of its industry studies11 study
recombinant FVIIaEarlier only
Evidence
  • NCT03935334 · AryoGen Pharmed Co. · Phase 3 · comparator · “Eptacog alfa, activated (Novoseven)” · registered Apr 2019
  • NCT02622321 · Hoffmann-La Roche · Phase 3 · background · “rFVIIa” · registered Dec 2015
  • NCT02484638 · CSL Limited · Phase 3 · comparator · “Eptacog alfa (activated)” · registered Jun 2015
  • NCT01625390 · Bayer · Phase 3 · comparator · “eptacog alfa [activated]” · registered Jun 2012
Novo Nordisk A/S88% of its industry studiesEU: Novo Nordisk A/S (EMA 1996) + 1 other00 studies
Factor VIIIEarlier onlyPhase 4 trial recorded
Evidence
  • NCT02847637 · Hoffmann-La Roche · Phase 3 · background · “Factor VIII (FVIII)” · registered Jul 2016
  • NCT01458106 · Sanofi · Phase 3 · background · “FVIII (PK subgroup only)” · registered Oct 2011
CSL Limited75% of its industry studies00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
GS1191-0445☆ Track1 live phase-3 study: NCT06833983Gritgen Therapeutics Co., Ltd.
efanesoctocog alfaApproved: EU 2024☆ Track1 live phase-3 study: NCT04644575Sanofi
FRSW107☆ Track2 live phase-3 studies: NCT07663903, NCT07684898Hangzhou Gensciences Biopharmaceutical Co., Ltd.
efanesoctocog alfaApproved: EU 2024☆ Track1 live phase-3 study: NCT06716814Swedish Orphan Biovitrum
fitusiranApproved: US 2025☆ Track2 live phase-3 studies: NCT07285460, NCT05662319Sanofi

The 5 in phase 3 with the nearest primary completion, of 17 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (12)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 17 Nov 2026 est.efanesoctocog alfa · Swedish Orphan Biovitrum · Phase 4 main aimNCT06752850 A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis — primary endpoint: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovial hypertrophy domain score decrease. · 37 enrolled
  • 30 Nov 2026 est.GS1191-0445 · Gritgen Therapeutics Co., Ltd. · Phase 3 main aimNCT06833983 To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A — primary endpoint: Annualized Bleeding Rate (ABR) · 50 enrolled
  • 31 Dec 2026 est.SR604 · Shanghai RAAS Blood Products Co., Ltd. · Phase 2 main aimNCT07644832 An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency — primary endpoint: Part A: Incidence of AEs/SAEs/AESI · 76 enrolled

9 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hemophilia A studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

49studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger. 56 (64%) take children under 18. 2 (2%) are for women only and 42 (48%) for men only; 10 (11%) take healthy volunteers.

Recruiting studies that take each age, of 88
AgeWomenMen
1025 (28%)38 (43%)
1843 (49%)78 (89%)
3040 (45%)76 (86%)
4040 (45%)75 (85%)
5040 (45%)73 (83%)
6539 (44%)68 (77%)
7535 (40%)56 (64%)
8535 (40%)53 (60%)

Across all 844 studies, recruiting or not: 47% stop at 75 or younger and 41% at 65; 66% take children; 2% are for women only and 60% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hemophilia A studies take

Of 91 phase 3 interventional studies under Hemophilia A, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 113 mo7–26 · 46 studies10 mo5–18 · 37 studies—
Phase 1/276 mo21–94 · 20 studies——
Phase 213 mo8–20 · 18 studies——
Phase 333 mo20–56 · 91 studies32 mo18–56 · 89 studies—
Phase 431 mo13–112 · 40 studies——
Interventional, no phase11 mo5–38 · 75 studies—11 mo5–38 · 72 studies
Observational45 mo25–79 · 131 studies58 mo34–79 · 53 studies36 mo15–96 · 78 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 844. Browse all 844 → or search them.